ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1881

Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals

Marina Pavía Pascual1, Isidro Jarque Canalias1, Jose Luis Morell2, Jesús Loarce Martos3, Lorena Montaño Tapia4, Olga Rusinovich1, Natalia de la Torre-Rubio1, Maria Machattou1, Pablo Navarro Palomo1, Maria Carmen Barbadillo Mateos1, Monica Fernandez Castro5, Blanca Garcia-Magallon1, Maria Hildegarda Godoy Tundidor1, Carolina Merino1, JESUS SANZ SANZ1, Jose Luis Andreu1 and Jose Campos1, 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 2Hospital Universitario Ramon y Cajal, Madrid, Spain, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, 5Puerta de Hierro Hospital, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), dermatomyositis, Myositis, pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Anti-transcriptional intermediary factor 1γ (anti-TIF 1γ) antibody is robustly linked with malignancy-associated dermatomyositis (DM) in adults, but its specificity varies widely between series. TIF 1γ can act either as a tumor promoter or suppressor and may act as an autoantigen.

To investigate the association between anti-TIF 1γ antibody positivity and the development of neoplasia.

Methods: A retrospective chart review was conducted among patients with positive anti-TIF 1γ antibodies detected by immunoblot from March 2019 to May 2022 in three tertiary hospitals. Demographic variables, creatine kinase (CK) values, other autoantibodies, associated autoimmune diseases (AID) and existence or not of cancer diagnosis were analyzed. To rule out malignancy, patients had to present a PET-CT scan without pathological findings or a chest computed tomography scan, a gynecological study and a digestive study without alterations. A descriptive statistical analysis was performed.

Results: 31 patients with anti-TIF 1γ antibodies were analyzed, 80.6% women, with a mean age of 61.6 years (31-96 years). The reason for requesting this antibody were: clinical features suggestive of DM in 12 patients (38.7%), muscle weakness in 9 (29%), interstitial lung disease (ILD) in 5 (16.1%), persistent elevation of CK elevation in 3 (9.7%), constitutional syndrome in 1 (3.2%) and antiphospholipid syndrome in 1 (3.2%). The mean time from symptoms onset to the detection of anti-TIF 1γ was 13 months (0-60 months). Twenty two patients (70.9%) had an associated AID (graph 1). Five patients (16.1%) had ILD with different patterns: usual interstitial pneumonia (n=2), nonspecific interstitial pneumonia (n=2) and cryptogenic organizing pneumonia (n=1). Only 11 (35.5%) had elevated CK levels at the time of antibody determination. Of our sample, 12 patients (38.7%) were diagnosed with cancer (graph 2). Of those, 9 (75%) had elevated CK levels and 8 (66.7%) had a diagnosis of DM. None of the patients diagnosed with cancer had IDL. In 5 patients (41.7%), the diagnosis of cancer was simultaneous with the diagnosis of anti-TIF 1γ antibodies; in 5 (41.7%), the diagnosis of the tumor preceded the finding of the antibodies; in 2 (16.7%), the finding of the antibodies preceded that of the tumor. Two patients have newly been diagnosed (< 6 months); 30 month survival after cancer diagnosis in the other 10 was 10%. In 17 patients (54.8%) no malignancy has been found so far in the annual cancer screening. In 2 patients (6.5%) no cancer screening was performed.

Conclusion: In our study, 61.5% of patients with DM and anti-TIF 1γ presented neoplasia, a prevalence similar to that established in other series (60-80%). Furthermore, 22.2% of patients with antibodies and without DM were diagnosed with cancer, suggesting that anti-TIF 1γ antibodies could also be associated with neoplasia in patients without DM. Patients with ILD did not present cancer, supporting the observation of previous studies in which the presence of ILD is a marker of low risk for neoplasia in patients with DM. HyperCKemia might predict the association with neoplasia in patients with anti-TIF 1γ antibodies.

Supporting image 1

Graph 1

Supporting image 2

Graph 2


Disclosures: M. Pavía Pascual, None; I. Jarque Canalias, None; J. Morell, None; J. Loarce Martos, None; L. Montaño Tapia, None; O. Rusinovich, None; N. de la Torre-Rubio, None; M. Machattou, None; P. Navarro Palomo, None; M. Barbadillo Mateos, None; M. Fernandez Castro, None; B. Garcia-Magallon, None; M. Godoy Tundidor, None; C. Merino, None; J. SANZ SANZ, None; J. Andreu, None; J. Campos, None.

To cite this abstract in AMA style:

Pavía Pascual M, Jarque Canalias I, Morell J, Loarce Martos J, Montaño Tapia L, Rusinovich O, de la Torre-Rubio N, Machattou M, Navarro Palomo P, Barbadillo Mateos M, Fernandez Castro M, Garcia-Magallon B, Godoy Tundidor M, Merino C, SANZ SANZ J, Andreu J, Campos J. Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-study-between-anti-tif1%ce%b3-antibody-and-development-of-neoplasia-in-three-tertiary-hospitals/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-study-between-anti-tif1%ce%b3-antibody-and-development-of-neoplasia-in-three-tertiary-hospitals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology